FibroGen Company Profile (NASDAQ:FGEN)

About FibroGen (NASDAQ:FGEN)

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology & Medical Research
Sub-Industry: N/A
Symbol: NASDAQ:FGEN
CUSIP: N/A
Web: www.fibrogen.com

Capitalization:

Market Cap: $4.22486 billion
Outstanding Shares: 71,195,000

Average Prices:

50 Day Moving Avg: $44.39
200 Day Moving Avg: $32.56
52 Week Range: $15.60 - $54.05

P/E:

Trailing P/E Ratio: N/A
Foreward P/E Ratio: -35.93
P/E Growth: 0.00

Sales & Book Value:

Annual Revenue: $117.9 million
Price / Sales: 32.55
Book Value: $3.24 per share
Price / Book: 16.64

Profitability:

EBIDTA: ($110,060,000.00)
Net Margins: -105.59%
Return on Equity: -64.42%
Return on Assets: -25.67%

Debt:

Debt-to-Equity Ratio: 0.39%
Current Ratio: 6.21%
Quick Ratio: 6.21%

Misc:

Average Volume: 860,448 shs.
Beta: 1.71
Short Ratio: 7.31

Frequently Asked Questions for FibroGen (NASDAQ:FGEN)

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

How were FibroGen's earnings last quarter?

FibroGen, Inc (NASDAQ:FGEN) issued its quarterly earnings data on Monday, August, 7th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.47) by $0.01. The business had revenue of $29 million for the quarter, compared to analyst estimates of $34.80 million. FibroGen had a negative net margin of 105.59% and a negative return on equity of 64.42%. View FibroGen's Earnings History.

When will FibroGen make its next earnings announcement?

FibroGen is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for FibroGen.

Where is FibroGen's stock going? Where will FibroGen's stock price be in 2017?

7 equities research analysts have issued 1 year target prices for FibroGen's shares. Their predictions range from $31.00 to $82.00. On average, they expect FibroGen's share price to reach $66.60 in the next year. View Analyst Ratings for FibroGen.

Who are some of FibroGen's key competitors?

Some companies that are related to FibroGen include Alkermes PLC (ALKS), Seattle Genetics (SGEN), Ionis Pharmaceuticals (IONS), Qiagen N.V. (QGEN), Alnylam Pharmaceuticals (ALNY), Icon Plc (ICLR), INC Research Holdings (INCR), Galapagos NV (GLPG), Exact Sciences Corporation (EXAS), Charles River Laboratories International (CRL), United Therapeutics Corporation (UTHR), PRA Health Sciences (PRAH), BIO-TECHNE Corp (TECH), PAREXEL International Corporation (PRXL), ACADIA Pharmaceuticals (ACAD), Puma Biotechnology (PBYI), Nektar Therapeutics (NKTR) and WuXi PharmaTech (Cayman) (WX).

Who are FibroGen's key executives?

FibroGen's management team includes the folowing people:

Thomas B. Neff, Chairman of the Board, Chief Executive Officer, Founder
Pat Cotroneo, Chief Financial Officer, Vice President - Finance
Frank H. Valone M.D., Senior Fellow, Clinical Development
K. Peony Yu M.D., Chief Medical Officer
Jeffrey L. Edwards, Independent Director
Jeffrey William Henderson, Independent Director
Thomas F. Kearns Jr., Independent Director
Kalevi Kurkijarvi Ph.D., Independent Director
Rory B. Riggs, Independent Director

When did FibroGen IPO?

(FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

Who owns FibroGen stock?

FibroGen's stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.30%), BlackRock Inc. (7.15%), FMR LLC (4.77%), State Street Corp (2.48%), Hillhouse Capital Management Ltd. (2.46%) and EcoR1 Capital LLC (2.23%). Company insiders that own FibroGen stock include Frank H Md Valone, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Miguel Madero, Pat Cotroneo, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr, Thomas F Kearns, Jr and Toshinari Tamura. View Institutional Ownership Trends for FibroGen.

Who sold FibroGen stock? Who is selling FibroGen stock?

FibroGen's stock was sold by a variety of institutional investors in the last quarter, including Omega Fund Management LLC, Acadian Asset Management LLC, JPMorgan Chase & Co., Candriam Luxembourg S.C.A., Castleark Management LLC, Pinnacle Associates Ltd., Capital Impact Advisors LLC and Royal Bank of Canada. Company insiders that have sold FibroGen stock in the last year include Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View Insider Buying and Selling for FibroGen.

Who bought FibroGen stock? Who is buying FibroGen stock?

FibroGen's stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, EcoR1 Capital LLC, Janus Henderson Group PLC, Vanguard Group Inc., Hillhouse Capital Management Ltd., BlackRock Inc., Farallon Capital Management LLC and State Street Corp. View Insider Buying and Selling for FibroGen.

How do I buy FibroGen stock?

Shares of FibroGen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is FibroGen's stock price today?

One share of FibroGen stock can currently be purchased for approximately $53.90.

MarketBeat Community Rating for FibroGen (NASDAQ FGEN)

Community Ranking:		3.1 out of 5 ( )
Outperform Votes:		124 (Vote Outperform)
Underperform Votes:		76 (Vote Underperform)
Total Votes:		200

MarketBeat's community ratings are surveys of what our community members think about FibroGen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for FibroGen (NASDAQ:FGEN) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	1 Hold Rating, 5 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:	Buy (Score: 3.00)
Consensus Price Target:	$66.60 (23.56% upside)

Analysts' Ratings History for FibroGen (NASDAQ:FGEN)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
9/14/2017	Stifel Nicolaus	Reiterated Rating	Buy	$80.00	Low
9/12/2017	Jefferies Group LLC	Reiterated Rating	Buy	$75.00	Low
8/9/2017	William Blair	Reiterated Rating	Outperform		Medium
8/8/2017	Leerink Swann	Reiterated Rating	Outperform -> Outperform	$52.00 -> $82.00	High
8/8/2017	Citigroup Inc.	Boost Price Target	Top Pick	$48.00 -> $65.00	High
7/21/2017	Goldman Sachs Group, Inc. (The)	Downgrade	Buy -> Neutral	$31.00	Medium
1/18/2017	Royal Bank Of Canada	Reiterated Rating	Buy		N/A
8/9/2016	Credit Suisse Group	Reiterated Rating	Buy	$37.00	N/A
9/23/2015	Lake Street Capital	Initiated Coverage	Hold	$25.00	N/A

(Data available from 9/22/2015 forward)

Earnings History for FibroGen (NASDAQ:FGEN)

Earnings by Quarter for FibroGen (NASDAQ:FGEN)

Earnings History by Quarter for FibroGen (NASDAQ FGEN)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/6/2017		($0.36)					N/A
8/7/2017	Q2 2017	($0.47)	($0.48)	$34.80 million	$29.00 million	View	Listen
5/9/2017	Q1 2017	($0.63)	($0.52)	$26.02 million	$26.89 million	View	Listen
3/1/2017	Q4 2016	($0.53)	($0.54)	$19.29 million	$31.91 million	View	Listen
11/8/2016	Q3	($0.63)	($0.38)	$24.30 million	$30.10 million	View	Listen
8/8/2016	Q2	$0.36	$0.35	$80.58 million	$89.28 million	View	Listen
5/9/2016	Q116	($0.56)	($0.45)	$16.89 million	$28.28 million	View	Listen
2/29/2016	Q4	($0.54)	($0.85)	$40.44 million	$24.44 million	View	Listen
11/12/2015	Q3	($0.61)	($0.74)	$28.74 million	$19.54 million	View	Listen
8/13/2015	Q215	$0.73	$0.83	$111.75 million	$120.55 million	View	Listen
5/12/2015	Q115	($0.53)	($0.78)	$34.00 million	$16.30 million	View	N/A
3/26/2015	Q414	($0.90)	($0.82)	$16.49 million	$16.11 million	View	Listen

(Data available from 1/1/2011 forward)

Earnings Estimates for FibroGen (NASDAQ:FGEN)

2017 EPS Consensus Estimate: ($2.05)
2018 EPS Consensus Estimate: ($1.17)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	2	($0.77)	($0.48)	($0.63)
Q2 2017	3	($0.47)	($0.43)	($0.45)
Q3 2017	3	($0.49)	($0.23)	($0.39)
Q4 2017	3	($0.69)	($0.49)	($0.59)
Q1 2018	1	($0.72)	($0.72)	($0.72)
Q2 2018	1	($0.69)	($0.69)	($0.69)
Q3 2018	1	$0.86	$0.86	$0.86
Q4 2018	1	($0.62)	($0.62)	($0.62)

(Data provided by Zacks Investment Research)

Dividend History for FibroGen (NASDAQ:FGEN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for FibroGen (NASDAQ:FGEN)

Insider Ownership Percentage: 14.90%
Institutional Ownership Percentage: 47.49%

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Insider Trades by Quarter for FibroGen (NASDAQ:FGEN)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/20/2017	Thomas B Neff	CEO	Sell	38,636	$53.46	$2,065,480.56
9/18/2017	Kalevi Kurkijarvi	Director	Sell	4,000	$46.65	$186,600.00
9/14/2017	K Peony Yu	Insider	Sell	2,851	$51.00	$145,401.00
9/14/2017	Thomas B Neff	CEO	Sell	38,636	$51.67	$1,996,322.12
9/13/2017	Rory B Riggs	Director	Sell	25,000	$51.92	$1,298,000.00
9/13/2017	Thomas B Neff	CEO	Sell	18,900	$51.29	$969,381.00
9/11/2017	Pat Cotroneo	VP	Sell	2,851	$49.45	$140,981.95
9/1/2017	Jorma Routti	Director	Sell	12,000	$47.36	$568,320.00
8/29/2017	Thomas B Neff	CEO	Sell	38,636	$43.73	$1,689,552.28
8/28/2017	Thomas B Neff	CEO	Sell	18,900	$43.04	$813,456.00
8/21/2017	K Peony Yu	Insider	Sell	7,500	$41.03	$307,725.00
8/17/2017	Kalevi Kurkijarvi	Director	Sell	2,000	$40.74	$81,480.00
8/8/2017	K Peony Yu	Insider	Sell	37,500	$50.58	$1,896,750.00
8/8/2017	Pat Cotroneo	VP	Sell	95,000	$50.61	$4,807,950.00
8/2/2017	Pat Cotroneo	VP	Sell	28,346	$33.97	$962,913.62
8/1/2017	K Peony Yu	Insider	Sell	10,000	$33.48	$334,800.00
7/25/2017	Thomas B Neff	CEO	Sell	38,636	$35.09	$1,355,737.24
7/24/2017	Thomas B Neff	CEO	Sell	18,900	$35.06	$662,634.00
7/17/2017	Kalevi Kurkijarvi	Director	Sell	2,000	$33.45	$66,900.00
7/10/2017	K Peony Yu	Insider	Sell	5,000	$32.98	$164,900.00
7/7/2017	Thomas B Neff	CEO	Sell	38,636	$33.38	$1,289,669.68
7/6/2017	Pat Cotroneo	VP	Sell	4,000	$34.00	$136,000.00
7/6/2017	Thomas B Neff	CEO	Sell	18,900	$33.53	$633,717.00
6/22/2017	Pat Cotroneo	VP	Sell	3,000	$32.00	$96,000.00
6/22/2017	Thomas B Neff	CEO	Sell	38,636	$31.52	$1,217,806.72
6/19/2017	Pat Cotroneo	VP	Sell	5,500	$30.00	$165,000.00
6/16/2017	Thomas B Neff	CEO	Sell	38,636	$29.40	$1,135,898.40
6/15/2017	Kalevi Kurkijarvi	Director	Sell	2,000	$28.50	$57,000.00
6/14/2017	K Peony Yu	Insider	Sell	3,721	$28.95	$107,722.95
6/12/2017	Pat Cotroneo	VP	Sell	2,891	$28.75	$83,116.25
6/12/2017	Toshinari Tamura	Director	Sell	30,000	$28.89	$866,700.00
6/6/2017	Thomas F Kearns Jr	Director	Sell	18,000	$28.71	$516,780.00
5/31/2017	Thomas B Neff	CEO	Sell	38,636	$26.21	$1,012,649.56
5/16/2017	Kalevi Kurkijarvi	Director	Sell	2,000	$27.40	$54,800.00
5/16/2017	Thomas B Neff	CEO	Sell	38,636	$27.70	$1,070,217.20
5/15/2017	Thomas B Neff	CEO	Sell	18,900	$27.75	$524,475.00
5/10/2017	K Peony Yu	Insider	Sell	5,000	$26.38	$131,900.00
4/25/2017	K Peony Yu	Insider	Sell	5,000	$28.00	$140,000.00
4/25/2017	Pat Cotroneo	VP	Sell	6,500	$28.00	$182,000.00
4/25/2017	Thomas B Neff	CEO	Sell	38,636	$26.92	$1,040,081.12
4/24/2017	Thomas B Neff	CEO	Sell	18,900	$26.35	$498,015.00
4/17/2017	Kalevi Kurkijarvi	Director	Sell	2,000	$25.25	$50,500.00
4/13/2017	Thomas B Neff	CEO	Sell	38,636	$24.79	$957,786.44
4/4/2017	Thomas B Neff	CEO	Sell	38,636	$23.92	$924,173.12
3/21/2017	Thomas B Neff	CEO	Sell	38,636	$24.34	$940,400.24
3/20/2017	Thomas B Neff	CEO	Sell	18,900	$24.88	$470,232.00
3/15/2017	Thomas B Neff	CEO	Sell	38,636	$25.07	$968,604.52
2/16/2017	Kalevi Kurkijarvi	Director	Sell	2,000	$24.45	$48,900.00
2/14/2017	Thomas B Neff	CEO	Sell	38,636	$23.94	$924,945.84
2/13/2017	Thomas B Neff	CEO	Sell	18,900	$23.97	$453,033.00
2/9/2017	Thomas B Neff	CEO	Sell	37,798	$23.46	$886,741.08
1/27/2017	Thomas B Neff	CEO	Sell	37,798	$23.29	$880,315.42
1/19/2017	Kalevi Kurkijarvi	Director	Sell	2,000	$24.90	$49,800.00
1/12/2017	Thomas B Neff	CEO	Sell	37,798	$23.85	$901,482.30
1/11/2017	Pat Cotroneo	VP	Sell	6,500	$24.00	$156,000.00
1/10/2017	K Peony Yu	Insider	Sell	5,000	$23.56	$117,800.00
12/28/2016	Thomas B Neff	CEO	Sell	37,798	$20.74	$783,930.52
12/16/2016	Rory B Riggs	Director	Sell	20,000	$20.87	$417,400.00
12/13/2016	Thomas B Neff	CEO	Sell	37,798	$21.24	$802,829.52
12/12/2016	Pat Cotroneo	VP	Sell	2,344	$22.05	$51,685.20
12/12/2016	Thomas B Neff	CEO	Sell	18,899	$21.48	$405,950.52
11/29/2016	Thomas B Neff	CEO	Sell	37,798	$22.80	$861,794.40
11/28/2016	Thomas B Neff	CEO	Sell	18,899	$22.74	$429,763.26
11/18/2016	Thomas F Kearns Jr	Director	Sell	18,000	$22.40	$403,200.00
11/17/2016	Thomas B Neff	CEO	Sell	37,798	$22.29	$842,517.42
11/1/2016	Thomas B Neff	CEO	Sell	37,798	$16.76	$633,494.48
10/19/2016	Thomas B Neff	CEO	Sell	37,798	$17.75	$670,914.50
10/18/2016	Thomas B Neff	CEO	Sell	18,899	$17.94	$339,048.06
10/4/2016	Thomas B Neff	CEO	Sell	18,899	$20.67	$390,642.33
10/3/2016	Thomas B Neff	CEO	Sell	18,899	$20.55	$388,374.45
9/21/2016	Thomas B Neff	CEO	Sell	37,798	$21.66	$818,704.68
9/14/2016	K Peony Yu	Insider	Sell	2,345	$18.66	$43,757.70
9/12/2016	Pat Cotroneo	VP	Sell	2,345	$18.22	$42,725.90
9/9/2016	Thomas B Neff	CEO	Sell	37,798	$18.99	$717,784.02
8/26/2016	Thomas B Neff	CEO	Sell	37,798	$17.80	$672,804.40
7/27/2016	Thomas B Neff	CEO	Sell	37,798	$18.38	$694,727.24
7/13/2016	Thomas B Neff	CEO	Sell	27,000	$17.50	$472,500.00
6/29/2016	Thomas B Neff	CEO	Sell	27,000	$16.02	$432,540.00
6/15/2016	Pat Cotroneo	CFO	Sell	1,796	$16.49	$29,616.04
6/15/2016	Thomas B Neff	CEO	Sell	27,000	$16.48	$444,960.00
6/10/2016	K Peony Yu	Insider	Sell	2,344	$17.96	$42,098.24
6/3/2016	Thomas B Neff	CEO	Sell	27,000	$18.99	$512,730.00
5/20/2016	Thomas B Neff	CEO	Sell	27,000	$17.68	$477,360.00
5/16/2016	Pat Cotroneo	CFO	Sell	6,107	$17.60	$107,483.20
5/3/2016	Thomas B Neff	CEO	Sell	27,000	$17.78	$480,060.00
4/20/2016	Thomas B Neff	CEO	Sell	27,000	$19.98	$539,460.00
4/19/2016	Thomas B Neff	CEO	Sell	13,500	$20.21	$272,835.00
4/5/2016	Thomas B Neff	CEO	Sell	27,000	$21.11	$569,970.00
4/1/2016	Frank H Md Valone	Insider	Sell	10,750	$21.11	$226,932.50
3/22/2016	Thomas B Neff	CEO	Sell	27,000	$18.74	$505,980.00
3/8/2016	Thomas B Neff	CEO	Sell	27,000	$19.62	$529,740.00
3/1/2016	Frank H Md Valone	Insider	Sell	10,750	$16.84	$181,030.00
2/23/2016	Thomas B Neff	CEO	Sell	27,000	$19.11	$515,970.00
2/22/2016	Thomas B Neff	CEO	Sell	13,500	$19.81	$267,435.00
2/16/2016	Frank H. Md Valone	insider	Sell	10,750	$18.41	$197,907.50
2/10/2016	Thomas B. Neff	CEO	Sell	27,000	$15.31	$413,370.00
1/29/2016	Thomas B. Neff	CEO	Sell	27,000	$19.41	$524,070.00
1/21/2016	Thomas F Kearns Jr	Director	Sell	1,572	$22.08	$34,709.76
1/14/2016	Thomas B. Neff	CEO	Sell	27,000	$23.69	$639,630.00
12/24/2015	Thomas F. Kearns, Jr.	Director	Sell	7,800	$30.88	$240,864.00
12/23/2015	Thomas B. Neff	CEO	Sell	27,000	$30.10	$812,700.00
12/11/2015	Thomas B. Neff	CEO	Sell	27,000	$29.59	$798,930.00
12/10/2015	K Peony Yu	VP	Sell	1,093	$28.96	$31,653.28
12/8/2015	Miguel Madero	Director	Sell	40,386	$30.49	$1,231,369.14
11/30/2015	K Peony Yu	VP	Sell	5,000	$30.00	$150,000.00
11/25/2015	Pat Cotroneo	CFO	Sell	5,000	$30.00	$150,000.00
11/24/2015	Thomas B. Neff	CEO	Sell	13,500	$28.98	$391,230.00
11/24/2015	Thomas F. Kearns, Jr.	Director	Sell	3,900	$29.00	$113,100.00
11/23/2015	Thomas B. Neff	CEO	Sell	13,500	$27.99	$377,865.00
11/23/2015	Thomas F. Kearns, Jr.	Director	Sell	3,900	$28.02	$109,278.00
11/17/2015	K Peony Yu	VP	Sell	5,000	$28.00	$140,000.00
11/10/2015	K Peony Yu	VP	Sell	5,000	$25.62	$128,100.00
11/9/2015	K Peony Yu	VP	Sell	2,500	$25.00	$62,500.00
11/2/2015	Frank H. Md Valone	insider	Sell	10,000	$23.18	$231,800.00
10/30/2015	Thomas B. Neff	CEO	Sell	27,000	$24.06	$649,620.00
10/21/2015	Thomas F. Kearns, Jr.	Director	Sell	7,800	$23.83	$185,874.00
10/19/2015	Frank H. Md Valone	insider	Sell	10,000	$23.00	$230,000.00
10/19/2015	K Peony Yu	VP	Sell	5,000	$24.00	$120,000.00
10/16/2015	K Peony Yu	VP	Sell	5,000	$21.46	$107,300.00
10/16/2015	Thomas B. Neff	CEO	Sell	27,000	$21.86	$590,220.00
10/2/2015	Thomas B. Neff	CEO	Sell	27,000	$21.59	$582,930.00
10/1/2015	Frank H. Md Valone	insider	Sell	10,000	$21.38	$213,800.00
9/18/2015	Thomas B. Neff	CEO	Sell	27,000	$29.10	$785,700.00
9/15/2015	Pat Cotroneo	CFO	Sell	1,093	$27.95	$30,549.35
9/14/2015	Rory B. Riggs	Director	Sell	50,000	$27.61	$1,380,500.00
9/11/2015	Miguel Madero	Director	Sell	20,600	$27.66	$569,796.00
9/10/2015	K Peony Yu	VP	Sell	1,093	$27.84	$30,429.12
9/10/2015	Pat Cotroneo	CFO	Sell	7,500	$27.33	$204,975.00
9/4/2015	Thomas B. Neff	CEO	Sell	13,500	$22.88	$308,880.00
9/3/2015	Thomas B. Neff	CEO	Sell	13,500	$22.92	$309,420.00
9/1/2015	Frank H. Md Valone	insider	Sell	10,000	$23.58	$235,800.00
7/23/2015	Thomas B Neff	CEO	Sell	27,000	$24.71	$667,170.00
7/20/2015	Frank H Md Valone	Insider	Sell	1,000	$23.70	$23,700.00
7/20/2015	Pat Cotroneo	CFO	Sell	7,881	$23.47	$184,967.07
7/9/2015	Thomas B Neff	CEO	Sell	27,000	$22.11	$596,970.00
7/6/2015	K Peony Yu	VP	Sell	5,381	$22.69	$122,094.89
6/25/2015	Thomas B Neff	CEO	Sell	27,000	$23.57	$636,390.00

(Data available from 1/1/2013 forward)

Headline Trends for FibroGen (NASDAQ:FGEN) Latest Headlines for FibroGen (NASDAQ:FGEN)

Source:

Date	Headline
	Insider Selling: FibroGen, Inc (FGEN) CEO Sells 38,636 Shares of Stock www.americanbankingnews.com - September 21 at 7:31 PM
	FibroGen, Inc (FGEN) Director Kalevi Kurkijarvi Sells 4,000 Shares www.americanbankingnews.com - September 20 at 10:22 PM
	FibroGen, Inc (FGEN) Director Sells $81,480.00 in Stock www.americanbankingnews.com - September 20 at 10:22 PM
	FibroGen Appoints Gerald Lema to Board of Directors - GlobeNewswire (press release) globenewswire.com - September 19 at 11:40 PM
	FibroGen Appoints Gerald Lema to Board of Directors finance.yahoo.com - September 19 at 6:37 PM
	FibroGen, Inc (FGEN) Given Buy Rating at Jefferies Group LLC www.americanbankingnews.com - September 17 at 8:58 PM
	K Peony Yu Sells 2,851 Shares of FibroGen, Inc (FGEN) Stock www.americanbankingnews.com - September 15 at 8:03 PM
	Thomas B. Neff Sells 38,636 Shares of FibroGen, Inc (FGEN) Stock www.americanbankingnews.com - September 15 at 7:24 PM
	Thomas B. Neff Sells 18,900 Shares of FibroGen, Inc (FGEN) Stock www.americanbankingnews.com - September 15 at 7:24 PM
	FibroGen, Inc (FGEN) Director Sells $1,298,000.00 in Stock www.americanbankingnews.com - September 15 at 7:24 PM
	FY2019 Earnings Estimate for FibroGen, Inc Issued By William Blair (FGEN) www.americanbankingnews.com - September 15 at 4:14 PM
	FibroGen, Inc (FGEN) Earns "Buy" Rating from Stifel Nicolaus www.americanbankingnews.com - September 14 at 1:04 PM
	FibroGen, Inc (FGEN) Expected to Announce Quarterly Sales of $41.34 Million www.americanbankingnews.com - September 14 at 8:20 AM
	FibroGen (FGEN) Reports Latest Data From Phase 2b Study of ... - StreetInsider.com www.streetinsider.com - September 14 at 1:05 AM
	FibroGen, Inc (FGEN) VP Pat Cotroneo Sells 2,851 Shares www.americanbankingnews.com - September 13 at 8:30 PM
	FibroGen (FGEN) Reports Latest Data From Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis www.streetinsider.com - September 13 at 8:03 PM
	Fibrogen Presents Latest Data From Phase 2b Study of Pamrevlumab in Idiopathic ... www.nasdaq.com - September 13 at 8:03 PM
	Fibrogen Presents Latest Data From Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at European Respiratory Society (ERS) International Congress 2017 finance.yahoo.com - September 13 at 8:03 PM
	FibroGen, Inc (FGEN) Receives Consensus Recommendation of "Buy" from Brokerages www.americanbankingnews.com - September 9 at 2:54 AM
	Is There Now An Opportunity In FibroGen Inc (FGEN)? finance.yahoo.com - September 6 at 11:35 PM
	Jorma Routti Sells 12,000 Shares of FibroGen, Inc (FGEN) Stock www.americanbankingnews.com - September 5 at 10:26 PM
	FibroGen Announces Pamrevlumab Oral and Poster Presentations at European Respiratory Society International Congress 2017 finance.yahoo.com - September 5 at 8:27 PM
	Analysts See 11% Upside For The Holdings of VBK www.nasdaq.com - August 31 at 6:33 PM
	FibroGen, Inc (FGEN) CEO Thomas B. Neff Sells 38,636 Shares www.americanbankingnews.com - August 30 at 10:20 PM
	K Peony Yu Sells 7,500 Shares of FibroGen, Inc (FGEN) Stock www.americanbankingnews.com - August 23 at 7:46 PM
	FibroGen, Inc. Announces Pricing of Follow-On Offering of Common Stock - Nasdaq www.nasdaq.com - August 17 at 4:47 AM
	FibroGen Prices Follow-On Offering 247wallst.com - August 16 at 11:44 PM
	Pre-Market Most Active for Aug 16, 2017 : TGT, FCAU, TEVA, NEFF, URBN, BABA, YY, FGEN, AAPL, TVIX, SNAP, QQQ - Nasdaq www.nasdaq.com - August 16 at 6:43 PM
	FibroGen, Inc. Announces Proposed Follow-On Offering of Common Stock - GlobeNewswire (press release) globenewswire.com - August 15 at 5:03 AM
	FibroGen, Inc (FGEN) Receives Consensus Rating of "Buy" from Brokerages www.americanbankingnews.com - August 15 at 2:56 AM
	FibroGen, Inc. Announces Proposed Follow-On Offering of Common Stock finance.yahoo.com - August 14 at 6:59 PM
	See what the IHS Markit Score report has to say about FibroGen Inc. finance.yahoo.com - August 12 at 5:54 PM
	FibroGen, Inc (NASDAQ:FGEN) Insider K Peony Yu Sells 37,500 Shares www.americanbankingnews.com - August 10 at 10:38 PM
	FibroGen, Inc (NASDAQ:FGEN) VP Pat Cotroneo Sells 95,000 Shares www.americanbankingnews.com - August 10 at 10:38 PM
	Q3 2017 Earnings Estimate for FibroGen, Inc (NASDAQ:FGEN) Issued By Jefferies Group www.americanbankingnews.com - August 10 at 11:56 AM
	Q3 2017 EPS Estimates for FibroGen, Inc (NASDAQ:FGEN) Increased by William Blair www.americanbankingnews.com - August 10 at 7:06 AM
	Leerink Swann Analysts Lower Earnings Estimates for FibroGen, Inc (NASDAQ:FGEN) www.americanbankingnews.com - August 10 at 7:06 AM
	FibroGen Inc. (FGEN) Leaped To A New High On Phase 2 Study Results www.rttnews.com - August 10 at 4:57 AM
	Strength Seen in FibroGen (FGEN): Stock Soars 48.2% - Nasdaq www.nasdaq.com - August 9 at 11:54 PM
	FibroGen Reaches Analyst Target Price - Nasdaq www.nasdaq.com - August 9 at 6:51 PM
	William Blair Weighs in on FibroGen, Inc's Q3 2018 Earnings (FGEN) www.americanbankingnews.com - August 9 at 1:30 PM
	FibroGen Inc. (FGEN) Has Soared To A New High On Phase 2 Study News www.nasdaq.com - August 8 at 11:26 PM
	Edited Transcript of FGEN earnings conference call or presentation 7-Aug-17 9:00pm GMT finance.yahoo.com - August 8 at 11:26 PM
	FibroGen shares surge 49% on positive mid-stage trial for pulmonary fibrosis therapy finance.yahoo.com - August 8 at 11:25 PM
	Why Fibrogen Shares Are Exploding finance.yahoo.com - August 8 at 11:25 PM
	BUZZ-US STOCKS ON THE MOVE-Valeant, Michael Kors, FibroGen, Ralph Lauren - Nasdaq www.nasdaq.com - August 8 at 6:24 PM
	BUZZ-US STOCKS ON THE MOVE-Michael Kors, Ralph Lauren, Gartner, FibroGen - Nasdaq www.nasdaq.com - August 8 at 6:24 PM
	FibroGen shares surge 49% on positive mid-stage trial for pulmonary fibrosis therapy - MarketWatch www.marketwatch.com - August 8 at 6:24 PM
	Why Fibrogen Shares Are Exploding - 24/7 Wall St. 247wallst.com - August 8 at 6:24 PM
	Why Did FibroGen (FGEN) Stock Hit All-Time High Today? finance.yahoo.com - August 8 at 6:24 PM